Trial Profile
A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary)
- Indications Malignant-mesothelioma
- Focus Registrational; Therapeutic Use
- Acronyms DENIM
- Sponsors Amphera
- 12 Sep 2023 Results presented at the 24th World Conference on Lung Cancer
- 20 Dec 2022 This trial has been completed in France, according to European Clinical Trials Database record.
- 12 Dec 2022 Primary endpoint (Overall survival rate) has not been met as per Amphera media release.